ADX71149
Addex is developing mGluR2 PAM under a 2004 collaboration agreement with Johnson & Johnson. The lead indications for this project include anxiety and schizophrenia. Several series of mGluR2 PAMs were discovered and some have advanced into preclinical development.
In 2007 Addex completed its responsibilities in the discovery phase of the agreement. Preclinical and clinical development are Johnson & Johnson’s responsibility, although Addex will participate via a joint steering committee. Addex is eligible for undisclosed milestone and royalty payments.
mGluRs & anxiety
mGluRs & schizophrenia